EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 3.0

Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial

Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park

Clinical and Molecular Hepatology · 2025

DOI: 10.3350/cmh.2024.0629 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Woo Hyun Paik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Curome Biosciences Co., Ltd, Korea Health Industry Development Institute, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: A clinical unmet need persists for medications capable of modulating the progression of primary sclerosing cholangitis (PSC). This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in PSC.

Methods

In this multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 trial, participants were assigned in a 2:1 ratio to receive either 100 mg of HK-660S or a placebo twice daily for 12 weeks. The primary outcomes were the reduction in serum alkaline phosphatase (ALP) levels and the percentage of participants showing improvements in PSC severity, as determined by magnetic resonance cholangiopancreatography with the Anali score. Secondary endpoints included changes in liver stiffness and adverse events.

Results

The analysis included 21 patients, 15 receiving HK-660S, and six receiving a placebo. Improvements in the Anali score were observed in 13.3% of the HK-660S group, with no improvements in the placebo group. HK-660S treatment resulted in a 15.2% reduction in mean ALP levels, compared to a 6.6% reduction in the placebo group. A stratified ad-hoc analysis based on baseline ALP levels showed a statistically significant response in the HK-660S group among those with ALP levels greater than twice the upper limit of normal, with a 50% responder rate (p=0.05). Additionally, 26.7% of the HK-660S group showed improvements in the enhanced liver fibrosis score, with no improvements in the placebo group. HK-660S was generally well tolerated.

Conclusions

HK-660S is well tolerated among patients with PSC and may improve bile duct strictures, decrease serum ALP levels, and reduce liver fibrosis (cris.nih.go.kr, Number KCT0006590).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingHumansMaleFemaleDouble-Blind MethodMiddle AgedAlkaline PhosphataseAdultTreatment OutcomeSeverity of Illness IndexCholangiopancreatography, Magnetic ResonanceLiver

Stichwörter der Autor:innen

Alkaline phosphataseCholangiopancreatography, magnetic resonanceLapachoneNicotinamide adenine dinucleotidePrimary sclerosing cholangitis

Substanzen

Alkaline Phosphatase

Autor:innen und Institutionen

  • Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine.
  • Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine.
  • Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine.
  • Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine.
  • Curome Biosciences Co., Ltd, Seoul, Korea.

Förderung

  • Curome Biosciences Co., Ltd
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare

Zitieren

APA

Paik, W. H., Park, J. K., Chung, M. J., Huh, G., Park, C. H., Lee, S. H., Jeong, H. S., Kim, H. J., & Park, D. H. (2025). Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0629

Vancouver

Paik WH, Park JK, Chung MJ, Huh G, Park CH, Lee SH, et al. Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0629

BibTeX
@article{Paik2025,
  author = {Paik, Woo Hyun and Park, Joo Kyung and Chung, Moon Jae and Huh, Gunn and Park, Ce Hwan and Lee, Sang Hyub and Jeong, Heon Se and Kim, Hee Jin and Park, Do Hyun},
  title = {Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  doi = {10.3350/cmh.2024.0629}
}
Kostenlos starten →